AbbVie stock closes at USD 265.21 as EU approval adds support

Published on 09/23/2026 at 13:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie stock closed at USD 265.21 on September 22, 2026, up 0.3 percent on the NYSE. Q2 revenue rose 10.2 percent year over year to USD 16.99 billion.

Fotorealistisches Pharma-Forschungslabor mit Petrischalen und Wissenschaftlern in Schutzkleidung — AbbVie Inc. US00287Y1091 fotorealistisches Pharma Forschungslabor mit Petrischalen Wissenschaftlern Immunologie Onkologie Biopharma, Illustration mit AI erstellt.

AbbVie Inc. (ISIN US00287Y1091) closed at USD 265.21 on the NYSE on September 22, 2026, gaining 0.3 percent from the prior close. The company also received European Commission approval for RINVOQ in pediatric arthritis, according to Yahoo Finance on September 23, 2026.

RINVOQ expands pediatric use

The European approval adds a pediatric indication for RINVOQ, AbbVie's immunology medicine, and provides a regulatory event alongside the stock's proximity to its yearly high. The shares traded between USD 263.10 and USD 266.74 on September 22, 2026, according to the dated market report.

The approval is relevant because AbbVie remains dependent on growth from newer medicines as its portfolio evolves. The regulatory decision therefore adds a concrete commercial milestone, while the market reaction was limited to a 0.3 percent daily gain.

Quarterly revenue rose 10.2 percent

AbbVie reported second-quarter 2026 EPS of USD 3.65 and revenue of USD 16.99 billion, beating the cited consensus estimates of USD 3.61 EPS and USD 16.80 billion revenue, according to MarketBeat on September 22, 2026.

The comparison is material: quarterly revenue increased 10.2 percent year over year, while EPS rose from USD 2.97 in the same quarter of the previous year to USD 3.65 in Q2 2026. AbbVie set Q3 2026 adjusted EPS guidance at USD 3.84 to USD 3.88, giving the next reporting period a defined earnings range.

Stock remains near yearly high

AbbVie had a 52-week range of USD 190.75 to USD 267.47 and a market capitalization of approximately USD 469.10 billion as of September 22, 2026. The closing price was USD 2.26 below the cited 52-week high, a difference of about 0.8 percent.

MarketBeat cited a consensus Moderate Buy rating and an average price target of USD 276.64 on September 22, 2026. That target stood USD 11.43 above the closing price, while the shares' valuation included a reported P/E ratio of 75.07.

AbbVie stock closes at USD 265.21

AbbVie stock closed at USD 265.21 on the NYSE on September 22, 2026, after reaching an intraday high of USD 266.74. The dated combination of Q2 revenue growth, Q3 EPS guidance of USD 3.84 to USD 3.88, and the RINVOQ approval defines the current investor debate without changing the stock's primary listing or currency.